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Purpose: To analyze the distribution of epidermal growth factor receptor (EGFR) muta-
tions; characterize the clinical and imageological features of lung squamous cell carcinoma
(LSCC) in a large population of patients; and assess correlations between clinical and
imageological characteristics and clinical outcomes of LSCC patients harboring EGFR
mutations.
Patients and methods: Three pathologists retrospectively evaluated the morphological
and immunohistochemical data of 2,322 patients with LSCC resected between February 2013
and December 2017. Data on the distribution of EGFR mutations and the clinical and
imageological characteristics of the patients were retrospectively collected. Correlations
between the EGFR mutation status and clinical outcomes were evaluated using univariate
and multivariate analyses.
Results: EGFR mutations were found in 3.4% of patients with LSCC and predominantly in
female and non-smoking patients. Tumor lesions in patients with EGFR-positive mutations were
more irregularly shaped than those in patients with EGFR-negative mutations (P = 0.045). In non-
smoking patients with LSCC, the proportion of marked spiculation was significantly higher in the
EGFR-positive group than in the EGFR-negative group (P = 0.043). No significant difference in
recurrence-free survival was noted between LSCC patients harboring EGFR-positive and those
harboring EGFR-negative mutations. No difference in metastases was observed between the
EGFR-positive and EGFR-negative cohorts.
Conclusion: Female gender, non-smoking habit, irregularly shaped tumor, and marked
spiculation might predict the presence of EGFR mutations in LSCC. The administration of
tyrosine kinase inhibitors to patients with LSCC after screening for EGFR mutations based
on their clinical and imageological features would likely result in a population with a greater
sensitivity to afatinib.
Keywords: EGFR mutation, lung squamous cell carcinoma, imageological feature,
recurrence-free survival
Introduction
Lung squamous cell carcinoma (LSCC) represents the second commonest histolo-
gical type of non-small cell lung cancer (NSCLC).1 Despite the decrease in the
incidence of LSCC in recent years, LSCC accounts for an estimated 30% and 20%
of lung cancers in men and women, respectively; approximately 2100,000 new
cases are reported worldwide each year.2–4 LSCC is highly associated with cigarette
smoking, and the majority of patients with LSCC are either current or former heavy
smokers.5 Therefore, it is not surprising that the genomic mutational profiles of
LSCC reflect genomic complexities and high overall mutational loads, which are
expected in tobacco carcinogenesis.3
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Epidermal growth factor receptor (EGFR) is the most
commonly mutated proto-oncogene in non-squamous
NSCLC, with typical mutation rates of approximately
10–15% in Caucasians and up to 50% in Asians.6–9
Targeting EGFR with tyrosine kinase inhibitors (TKIs)
has become the cornerstone for the management of
advanced non-squamous NSCLCs harboring activating
mutations of the EGFR gene.
However, genomic alterations in LSCC have not been
completely characterized so far. The most frequent somatic
mutations and alterations in LSCC have been identified in
TP53, PIK3CA, FGFR1, MET, and DDR2, and none of
these biomarkers have been validated as predictive for the
particular targeted therapies.3,10 Platinum-based che-
motherapy continues to remain the first-line treatment for
LSCC owing to the lack of an effective targeted therapy
for this disease.11
Although activating mutations of EGFR are uncommon
in LSCC, patients with the genetic mutations of this sub-
type might benefit from EGFR-TKI-targeted therapies
with lower side effects and toxicities than those of che-
motherapy, thus highlighting the benefit of EGFR mutation
status identification in patients with LSCC.12
Cumulative epidemiologic studies have identified sev-
eral clinicopathological factors such as gender, smoking
habits, histology of adenocarcinoma (ADC), and ethnicity
that may be associated with a high prevalence of EGFR
mutations.13–15 In addition, other tumor imageological
characteristics and biological parameters may have a pre-
dictive effect on the EGFR mutation status in lung
ADC.15,16 Unfortunately, the distribution of EGFR muta-
tions in LSCC is poorly investigated, and the imageological
features related to EGFR mutations in LSCC remain
unclear. Therefore, in this study, we aimed to analyze the
distribution of EGFR mutations and the clinical and mor-
phological features of a large population of LSCC patients
who underwent therapeutic resection and adjuvant che-
motherapy post-surgery. Additionally, we assessed the cor-
relations between clinical and imageological characteristics
and the clinical outcome of LSCC patients with EGFR
mutations.
Methods
Patient Cohort
All patients with solitary LSCC who underwent surgical
resection at the Shanghai Pulmonary Hospital, affiliated to
the Tongji University in China, between February 2013
and December 2017 were examined. A total of 2,322
patients were included in the study. All tumors were clas-
sified according to the 2015 World Health Organization
classification and staged according to the seventh edition
of the TNM system. The TNM stages include three com-
ponents: primary tumor (T), nodal status for metastasis
(N), and metastasis at distant organs (M). Written
informed consents were obtained from all the patients,
and the study was approved by the Institutional Review
Board at the Shanghai Pulmonary Hospital.
Histologic Evaluation And Confirmation
Hematoxylin and eosin (H&E)-stained sections of the tumor
were blindly reviewed by three experienced pulmonary
pathologists. Immunohistochemical (IHC) staining was per-
formed to exclude mixed and inconspicuous ADC compo-
nents. The lung tissue sections were deparaffinized three
times with xylene and dehydrated through a graded series of
ethanol. Endogenous peroxidase activity was quenched with
3%H2O2 inwater for 10min. Antigen retrieval was performed
by heating the slides in 0.1 M sodium citrate (pH 6.0) for
10 min. The sections were then incubated with primary anti-
bodies for 30 min at room temperature. Sections incubated
with antibody diluents were used as negative controls. The
sections were developed using the Dako EnVision™ visuali-
zation system (Dako Cytomation, CA, USA), and the follow-
ing antibodies were used for IHC staining: ΔNP63 (p40;
Calbiochem, Darmstadt, Germany) and cytokeratin 5/6
(CK5/6; Dako).
DNA Extraction And EGFR Mutation
Analysis
The Amplification Refractory Mutation System was used for
molecular diagnosis in this study. Between February 2013
and December 2015, genomic DNAwas extracted from fresh
tissues using the QIAamp DNATissue Kit (Qiagen, Hilden,
Germany). Mutations in the EGFR gene were detected using
the Amoy Diagnostics Kit (AmoyDx, Xiamen, China)
according to the manufacturer’s instructions.17 Between
January 2016 and December 2017, DNA was extracted
from five serial slices of a 5-μm-thick paraffin section using
the DNA Formalin-Fixed Paraffin-Embedded Tissue Kit
(Qiagen, Hilden, Germany). EGFR mutations were detected
using the ACCB Diagnostics Kit (ACCB, Beijing, China)
according to the manufacturer’s protocol18 The test could
detect mutations at a sensitivity of 1% in no less than 5 ng/μL
of the DNA sample.
Gao et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Cancer Management and Research 2019:119018
Clinical Assessment
Data regarding patient characteristics at the time of lung
cancer diagnosis, including age, sex, smoking history,
tumor size, pathological TNM stage, tumor morphology,
location, histological type, internal structure, lobulation,
margin, shape, spiculation, and texture were collected ret-
rospectively. Recurrence-free survival (RFS) was calcu-
lated from the date of surgical resection until the date of
confirmed recurrence from any cause. Patients who were
alive at the time of analysis were censored at the last
known date of follow-up. All patients were followed up
for more than 12 months.
Statistical Analysis
We compared the clinicopathological features of EGFR-
positive patients with those of EGFR-negative patients.
The EGFR-negative patients were consecutively selected
from our department between January 2016 and March
2016.19 RFS measurements were obtained from EGFR-
negative patients who underwent surgery on the same
day as EGFR-positive patients or at a time that was closest
to that of EGFR-positive patients. No differences in clin-
icopathological features were detected between those two
non-mutated populations (Table 1). Statistically significant
differences in categorical variables between the groups
were analyzed using the χ2 or Fisher’s exact test, as appro-
priate. RFS was estimated by the Kaplan-Meier method,
and the log rank test was used for the univariate analysis.
The Cox-proportional hazard model was used for the mul-
tivariate analysis. The covariates considered for the multi-
variate analysis were gender, age, TNM stage, tumor size,
and smoking status. Two-sided P values of <0.05 were
considered statistically significant. SPSS version 20.0 for
Windows (IBM SPSS Statistics, Chicago, IL) was used for
the statistical analyses.
Results
Confirmation Of LSCC By H&E Staining
And IHC Analysis
The expression of CK5/6 and ΔNP63 (p40) is consid-
ered a classical hallmark of LSCC.20–22 In the present
study, three pathologists retrospectively evaluated the
H&E- and IHC-stained sections from the 2,322 patients
with LSCC. The sections were strongly positive for
CK5/6 and ΔNP63 (Supplementary Figure). Based on
morphological and IHC data, all included tumors were
confirmed to be LSCC.
Distribution Of The EGFR Mutation In
LSCC
EGFR gene mutations were detected in 80 of the 2,322
samples (mutation rate, 3.4%). Exon 19 deletions (19-del)
and the L858R mutations in exon 21 comprised 48.75%
and 32.5% of all EGFR mutations, respectively, in LSCC
patients. The uncommon EGFR mutations observed in
the cohort included 5 (6.25%) cases of 20-ins mutations,
3 (3.75%) of T790M mutations, 3 (3.75%) of G719X
mutations, and 1 (1.25%) of L861Q mutation. The dual
T790M and L858R mutations were observed in 2 (2.5%)
patients and dual G719X and L861Q mutations were
found in 1 (1.25%) patient (Figure 1).
Clinicopathological Characteristics
The clinicopathological characteristics of 80 EGFR-positive
and 95 EGFR-negative cases are listed in Table 2. No differ-
ences in age, drinking, TNM stage, tumor size, and site were
observed between the two groups. However, the proportion
Table 1 The Clinicopathological Characteristics Of Two EGFR-
Negative Populations
For CF For RFS P
Sex 0.5
Female 6 7
Male 86 85
Age 0.371
≤60 27 24
>60 65 70
Somking 0.486
Non-somker 30 30
Previous smoker 16 11
Current smoker 42 49
Drinking 0.508
Non-drinking 84 84
Drinking 7 6
TNM stage 0.529
I 34 26
II 17 20
III & IV 20 15
Tumor size 0.4
≤3cm 37 38
>3cm 55 52
Site 1
Left 45 44
Right 47 48
Abbreviations: CF, clinicopathological features; RFS, recurrence-free survival.
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of females was higher in the EGFR-positive group than in the
EGFR-negative group, with statistical significance notwith-
standing (P = 0.064). The number of patients who never
smoked was significantly higher in the EGFR-positive
group than in the EGFR-negative group (P = 0.006).
Patient Imageological Characteristics
The imageological characteristics of 80 EGFR-positive
and 95 EGFR-negative patients with LSCC, including the
internal structure, margin, shape, and presence of lobula-
tion and spiculation, are shown in Table 3. No differences
in internal structure, margin, lobulation, and spiculation
were detected between the two groups. Irregularly shaped
lesions were more common in the EGFR-positive group
than in the EGFR-negative group (P = 0.045).
The imageological characteristics of EGFR-positive and
EGFR-negative non-smoker patients with LSCC were
examined because the majority of patients with EGFR-
mutated LSCCs were generally non-smokers. As shown in
Table 4, no differences in internal structure, margin, shape,
and lobulation were detected between the two groups of
non-smoker patients. The proportion of marked spiculation
was significantly higher in the EGFR-positive group than in
the EGFR-negative group (P = 0.043; Table 4; Figure 2).
Analysis Of RFS
No significant difference in RFS was identified between the
EGFR-positive (45.9 months) and EGFR-negative (49.5
months) patients. The patients were then stratified into
two subgroups based on their need for adjuvant therapy
after surgery (Figure 3). The RFS of EGFR-positive
patients in both the stage IA group (no specific treatment,
52.5 months vs. 47.9 months) and the stage IB-IIIA group
Figure 1 A comprehensive view of EGFR mutations in patients with LSCC (n = 80).
Table 2 The Clinicopathological Characteristics Of 175 Patients
With LSCC
EGFR Positive EGFR Negative P
Sex 0.064
Female 14 7
Male 63 85
Age 0.199
≤60 26 24
>60 54 70
Somking 0.006
Non-somker 43 30
Previous smoker 5 11
Current smoker 26 49
Drinking 0.116
Non-drinking 66 86
Drinking 16 6
TNM stage 0.533
I 39 26
II 19 20
III & IV 19 15
Tumor size 0.249
≤3cm 28 38
>3cm 50 52
Site 0.169
Left 32 46
Right 47 48
Table 3 The Imageological Characteristics Of 175 Patients With
LSCC
EGFR Positive EGFR Negative P
Internal structure 0.356
Homogeneous 13 14
Heterogeneous 63 73
Lobulation 0.084
Marked 62 73
None 5 14
Margin 0.429
Poorly defined 61 81
Sharp 6 6
Shape 0.045
Regular 3 12
Irregular 64 75
Spiculation 0.129
Marked 49 55
None 18 32
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(adjuvant therapy, 48.1 months vs. 42.4 months) was not
significantly different from that in EGFR-negative patients.
Metastasis Of Patients
Of the 175 patients with LSCC, 127 with follow-up infor-
mation were included in the analysis; among them, 56
were EGFR-positive and 71 had wild-type EGFR (WT).
The incidence of brain metastases was 1.79% (1/56) in
EGFR-positive patients and 1.41% (1/71) in EGFR WT
patients (P = 0.038; hazard ratio [HR], 1.4). Furthermore,
the incidences of bone, lung and multiple-site metastases
were 3.57% (2/56) vs 1.41% (1/71), 5.36% (3/56) vs
1.41% (1/71), and 1.79% (1/56) vs 1.41% (1/71) in
EGFR-positive and EGFR WT patients. No significant
differences in single-site (brain, bone, and lung) and multi-
ple-site metastases were observed between EGFR-positive
and EGFR WT patients (Table 5).
Discussion
The incidence of EGFR mutations, imageological features,
and clinical outcomes were evaluated in a large cohort of
postoperative patients with LSCC in the present study.
EGFR mutations were detected with increased frequency
in females and non-smokers. Moreover, the tumors in
patients with EGFR-positive mutations were more irregu-
larly shaped and demonstrated marked spiculation com-
pared with those with EGFR-negative mutations. Thus,
patients with active EGFR mutations might benefit from
second-generation EGFR-TKIs treatments.23,24
Consistent with the findings of previous studies,25,26
the EGFR mutation rate in patients with LSCC in the
current study was 3.4%; however, this value was much
lower than that reported in patients with ADC.27 Exon 19-
del and L858R mutations in exon 21 of the EGFR gene are
the two commonest mutations that predict the favorable
Table 4 The Imageological Characteristics Of Non-Smokers
With LSCC
EGFR Positive EGFR Negative P
Internal structure 0.349
Homogeneous 28 24
Heterogeneous 9 5
Lobulation 0.363
Marked 34 25
None 3 4
Margin 0.092
Poorly defined 33 29
Sharp 4 0
Shape 0.221
Regular 1 3
Irregular 36 26
Spiculation 0.043
Marked 31 25
None 6 4
Figure 2 Imageological characteristics of non-smoking LSCC patients with (A) or
without (B) EGFR mutations.
Figure 3 Kaplan-Meier curves of recurrence-free survival (RFS) according to the adjuvant therapy status in postoperative patients with LSCC. (A) RFS for EGFR-mutation
patients with stage IA LSCC. (B) RFS for EGFR-mutation patients with stage IB-IIIA LSCC.
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efficacy of EGFR-TKIs.28 The L858R mutation is report-
edly the commonest type of mutation in patients with
ADC, whereas exon 19-del is dominant in LSCC. In the
present study, exon 19-del and EGFR L858R mutations
accounted for 48.75% and 32.5% of all EGFR mutations,
respectively, in patients with LSCC. The mutation rate of
the EGFR L858R mutation in patients with LSCC was
lower than that reported in patients with non-squamous
NSCLC.29,30 In contrast, the uncommon EGFR mutations
observed in the cohort included 5 (6.25%) cases of 20-ins
mutations and 3 (3.75%) of T790M mutations. The fre-
quency of uncommon mutations (20-ins and T790M) in
LSCC was higher than that in NSCLC, which might partly
explain the poor response to EGFR-TKIs.31
Evaluation of the clinicopathological characteristics of
the patients revealed the absence of any association between
EGFR mutation and the majority of clinicopathological
characteristics. However, the proportion of females in the
EGFR-positive group was higher than that in the EGFR-
negative group, although statistical significance was not
achieved (P = 0.064). In addition, EGFR mutations were
more frequent in non-smokers than in previous smokers or
current smokers (P = 0.006). Moreover, based on the logis-
tic regression analysis, smoking was negatively correlated
(odds ratio [OR], 0.68; 95% confidence interval [CI],
0.476–0.973; P = 0.035) with EGFR mutations (data not
shown). This is consistent with the clinical characteristics of
EGFR mutations in ADC and LSCC.13–15,32
No differences in tumor metastatic capability and
patient outcome were noted; however, the imageological
characteristics were different between EGFR-positive and
EGFR-negative LSCC patients. The LSCC lesions were
more irregularly shaped in the EGFR-positive group than
in the EGFR-negative group (P = 0.045). After subgroup-
ing of the non-smoker LSCC patients into EGFR-positive
and EGFR-negative groups, significantly higher amounts
of marked spiculation were detected in the EGFR-positive
group than in the EGFR-negative group (P = 0.043).
Nonetheless, the logistic regression analysis did not show
any correlations between the imageological features and
EGFR mutations.
Targeting EGFR with TKIs has become the cornerstone
for the management of advanced non-squamous NSCLC
harboring activating EGFR mutations; however, the rele-
vance of EGFR inhibitors in LSCC is poorly defined. The
role of erlotinib in the treatment of LSCC, irrespective of
the EGFR mutation status, has been evaluated in several
clinical trials, including the observational PEPiTA study,33
the BR.21 trial,34 the SATURN study,35 the TRUSTstudy,36
the TITAN,37 and the DELTA trial.38 Data from these clin-
ical trials demonstrated that as a maintenance treatment
option, the therapeutic effects of erlotinib were similar to
those of first- or second-line chemotherapy. Furthermore,
the role of afatinib in the treatment of LSCC has been
evaluated in several clinical trials.39 Shun Lu and his col-
leagues conducted a post hoc analysis of the data of patients
in the LUX-Lung 8 trial conducted in mainland China.23
Compared with erlotinib, afatinib reduced the risk of dis-
ease progression or death in the Chinese subgroup by 30%
(HR, = 0.70; 95% CI, 0.38–1.27), thereby indicating that
afatinib may be considered as a feasible treatment option for
Chinese patients with advanced LSCC following the pro-
gression of the disease after platinum-based chemotherapy.
Yuri Taniguchi and his colleagues showed that the admin-
istration of afatinib to LSCC patients who were selected
using the EGFR mutation test based on the underlying
pulmonary disease and smoking status would likely result
in a population with a greater sensitivity to afatinib.39
This study has several limitations. First, despite the
inclusion of large-scale data compared with those of pre-
vious studies, the patients belonged to a single center,
which can lead to a bias in the selection of patients.
Second, this was a retrospective study, and we could not
collect any data related to targeted therapy (although afa-
tinib has been shown to be effective for LSCC patients
harboring activating EGFR mutations); therefore, the effi-
cacy of EGFR-TKIs was not evaluated in this study. The
use of molecular testing for early-stage lung cancer
Table 5 The Metastatic Site And Number Of Patients With LSCC
Single Site Metastasis Multiple Site Metastasis P
Brain P Bone P Lung P Others P
EGFR 0.689 0.411 0.542 0.63 0.689
positive 1/56 2/56 3/56 3/56 1/56
negative 1/71 1/71 1/71 4/71 1/71
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patients based on the availability of high-quality resection
samples will prove beneficial, particularly for those who
present with disease progression, thus providing them with
another option during treatment planning.40
The most important predictors of the presence of EGFR
mutations in LSCC were female gender, non-smoking habit,
irregularly-shaped lesions, and marked spiculation (imageolo-
gical finding). The administration of EGFR-TKIs to patients
with LSCC after screening forEGFRmutations on the basis of
their clinical and imageological features would likely result in
a population with a greater sensitivity to afatinib.
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